GILLIS STEVEN — SEC insider filings
SEC reporting owner CIK 1229592. 50 insider filings on record with FilingPulse; latest filed 2026-11-05.
Transaction summary — filings shown
Covers all 50 filings on record, filed 2020-09-01 to 2026-11-05. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 43 legs across 24 filings — 29,300,242 shares, $254,119,953 total (shares × price as filed on priced legs).
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 16,000 shares, $39,840 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 144.
- Largest priced transaction: purchase of 1,432,224 shares @ $18.00 ($25,780,032) in Metsera, Inc., filed 2025-02-03.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Prime Medicine, Inc. (PRME) | 10% owner | 3 | 4 legs · 7,030,300 sh · $43,599,990 | — | 6 |
| Metsera, Inc. (MTSR) | Director, 10% owner | 2 | 2 legs · 2,222,222 sh · $39,999,996 | — | 9 |
| Lyell Immunopharma, Inc. (LYEL) | 10% owner | 2 | 2 legs · 2,809,352 sh · $37,499,977 | — | — |
| Neumora Therapeutics, Inc. (NMRA) | 10% owner | 9 | 20 legs · 3,922,764 sh · $36,430,001 | — | 12 |
| Kardigan, Inc. (KARD) | Director, 10% owner | 2 | 1 leg · 1,250,000 sh · $20,000,000 | — | 4 |
| Aspen Neuroscience, Inc. (ASPE) | 10% owner | 2 | 3 legs · 1,333,333 sh · $19,999,995 | — | 18 |
| Seaport Therapeutics, Inc. (SPTX) | 10% owner | 1 | 1 leg · 1,100,000 sh · $19,800,000 | — | 4 |
| DA32 Life Science Tech Acquisition Corp. (DALS) | 10% owner | 3 | 1 leg · 1,600,000 sh · $16,000,000 | — | 3 |
| Sana Biotechnology, Inc. (SANA) | 10% owner | 2 | 3 legs · 1,818,181 sh · $9,999,996 | — | 14 |
| Codiak BioSciences, Inc. (CDAK) | Director | 7 | 2 legs · 5,235,000 sh · $3,525,000 | — | 12 |
+9 more issuers among the filings shown — every filing appears in the table below.
Insider filings — GILLIS STEVEN
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-05 | 4 | Lyell Immunopharma, Inc. (LYEL) jointly with ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, CRANDELL KEITH, NELSEN ROBERT, Burow Kristina, BERNS PAUL L, BYBEE CLINTON | Purchase (P): 2,321,262 @ $10.77 | EDGAR |
| 2026-11-02 | 4 | Aspen Neuroscience, Inc. (ASPE) jointly with ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners X, LLC, CRANDELL KEITH, Burow Kristina, NELSEN ROBERT | Purchase (P): 66,666 @ $15 · Conversion (C): 187,182 · Conversion (C): 298,258 · Conversion (C): 286,304 · Conversion (C): 295,490 · Conversion (C): 259,948 · +15 more | EDGAR |
| 2026-10-29 | 3 | Aspen Neuroscience, Inc. (ASPE) jointly with ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners X, LLC, CRANDELL KEITH, Burow Kristina, NELSEN ROBERT | Holdings only — no transactions reported | EDGAR |
| 2026-10-19 | 4 | CITY THERAPEUTICS, INC. (CTY) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, Burow Kristina | Conversion (C): 3,294,900 · Conversion (C): 5,482,309 · Conversion (C): 2,027,006 · Purchase (P): 170,000 @ $18 · Conversion (C): 3,000,000 (derivative) @ $0 · Conversion (C): 4,991,633 (derivative) @ $0 · +1 more | EDGAR |
| 2026-10-15 | 3 | CITY THERAPEUTICS, INC. (CTY) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, Burow Kristina | Holdings only — no transactions reported | EDGAR |
| 2026-07-06 | 4 | Boundless Bio, Inc. (BOLD) jointly with CRANDELL KEITH, BYBEE CLINTON, NELSEN ROBERT, Burow Kristina | Option exercise (M): 16,000 @ $1.03 · Sale (S): 16,000 @ $2.49 · Option exercise (M): 16,000 (derivative) @ $0 | EDGAR |
| 2026-07-06 | 4 | TAKEDA PHARMACEUTICAL CO LTD (TAK) | Grant/award (A): 3,800 @ $0 · Disposition to issuer (D): 1,152 (derivative) @ $4,931.20 · Grant/award (A): 1,319 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Kardigan, Inc. (KARD) jointly with ARCH Venture Partners XIII, LLC, ARCH Venture Partners XIII, L.P., ARCH Venture Fund XIII, L.P., CRANDELL KEITH, NELSEN ROBERT, Burow Kristina | Purchase (P): 1,250,000 @ $16 | EDGAR |
| 2026-06-22 | 4 | Kardigan, Inc. (KARD) jointly with ARCH Venture Partners XIII, LLC, ARCH Venture Partners XIII, L.P., ARCH Venture Fund XIII, L.P., CRANDELL KEITH, NELSEN ROBERT, Burow Kristina | Conversion (C): 13,792,035 · Conversion (C): 5,148,587 (derivative) · Conversion (C): 1,204,000 (derivative) · Conversion (C): 2,306,401 (derivative) | EDGAR |
| 2026-05-04 | 4 | Seaport Therapeutics, Inc. (SPTX) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, NELSEN ROBERT, Burow Kristina | Conversion (C): 2,513,686 · Conversion (C): 2,681,265 · Purchase (P): 1,100,000 @ $18 · Conversion (C): 2,513,686 (derivative) @ $0 · Conversion (C): 2,681,265 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Lyell Immunopharma, Inc. (LYEL) jointly with ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, CRANDELL KEITH, NELSEN ROBERT, Burow Kristina, BERNS PAUL L, BYBEE CLINTON | Purchase (P): 488,090 @ $25.61 | EDGAR |
| 2025-11-14 | 4 | Metsera, Inc. (MTSR) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Fund XII, L.P., ARCH Venture Partners XII, L.P., ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, CRANDELL KEITH, NELSEN ROBERT | Disposition to issuer (D): 18,503,128 · Disposition to issuer (D): 8,313,680 | EDGAR |
| 2025-10-29 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, NELSEN ROBERT, BYBEE CLINTON | Purchase (P): 1,915,700 @ $2.61 | EDGAR |
| 2025-08-01 | 4 | Prime Medicine, Inc. (PRME) jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., CRANDELL KEITH, Burow Kristina | Purchase (P): 3,030,300 @ $3.30 | EDGAR |
| 2025-02-03 | 4 | Metsera, Inc. (MTSR) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Fund XII, L.P., ARCH Venture Partners XII, L.P., ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, CRANDELL KEITH, NELSEN ROBERT | Conversion (C): 16,006,949 · Conversion (C): 7,523,682 · Purchase (P): 1,432,224 @ $18 · Purchase (P): 789,998 @ $18 · Conversion (C): 19,933,333 (derivative) · Conversion (C): 15,000,000 (derivative) · +3 more | EDGAR |
| 2024-06-10 | 4 | Rapport Therapeutics, Inc. (RAPP) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, NELSEN ROBERT, Burow Kristina | Conversion (C): 3,728,738 @ $0 · Conversion (C): 20,000,000 (derivative) @ $0 · Conversion (C): 11,924,138 (derivative) @ $0 | EDGAR |
| 2024-04-04 | 4 | Boundless Bio, Inc. (BOLD) jointly with CRANDELL KEITH, BYBEE CLINTON, NELSEN ROBERT | Conversion (C): 589,743 · Conversion (C): 787,545 · Conversion (C): 1,048,433 · Purchase (P): 66,667 @ $16 · Purchase (P): 133,333 @ $16 · Conversion (C): 424,908 (derivative) · +6 more | EDGAR |
| 2024-02-20 | 4 | Prime Medicine, Inc. (PRME) jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., CRANDELL KEITH, Burow Kristina | Purchase (P): 3,200,000 @ $6.25 | EDGAR |
| 2024-02-12 | 4 | Sana Biotechnology, Inc. (SANA) jointly with CRANDELL KEITH, BYBEE CLINTON, Burow Kristina | Purchase (P): 363,637 @ $5.50 · Purchase (P): 727,272 @ $5.50 · Purchase (P): 727,272 @ $5.50 | EDGAR |
| 2023-12-12 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, NELSEN ROBERT, BYBEE CLINTON | Other (J): 703,061 · Other (J): 1,176,593 | EDGAR |
| 2023-11-15 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, NELSEN ROBERT | Purchase (P): 31,653 @ $11.75 · Purchase (P): 3,357 @ $11.98 | EDGAR |
| 2023-11-13 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, NELSEN ROBERT | Purchase (P): 69,127 @ $10.78 · Purchase (P): 23,124 @ $11.79 · Purchase (P): 31,079 @ $10.53 · Purchase (P): 11,844 @ $11.37 · Purchase (P): 5,431 @ $11.75 | EDGAR |
| 2023-11-07 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, NELSEN ROBERT | Purchase (P): 22,420 @ $11.38 · Purchase (P): 43,082 @ $11.55 · Purchase (P): 30,192 @ $11.50 | EDGAR |
| 2023-09-29 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, NELSEN ROBERT | Purchase (P): 16,841 @ $13.06 · Purchase (P): 25,110 @ $13.69 · Purchase (P): 34,560 @ $13.98 | EDGAR |
| 2023-09-27 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, NELSEN ROBERT | Purchase (P): 34,000 @ $11.73 · Purchase (P): 24,504 @ $12.31 | EDGAR |
| 2023-09-25 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, NELSEN ROBERT | Purchase (P): 40,000 @ $11.14 · Purchase (P): 30,773 @ $10.80 · Purchase (P): 29,967 @ $11.65 | EDGAR |
| 2023-09-20 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, NELSEN ROBERT, BYBEE CLINTON | Conversion (C): 684,167 · Conversion (C): 1,144,973 · Conversion (C): 6,895,021 · Conversion (C): 6,576,400 · Conversion (C): 2,124,143 · Purchase (P): 1,500,000 @ $17 · +5 more | EDGAR |
| 2023-08-10 | 4 | DA32 Life Science Tech Acquisition Corp. (DALS) jointly with ARCH Venture Fund XI, L.P., ARCH Venture Partners XI, L.P., ARCH Venture Partners XI, LLC, NELSEN ROBERT, Burow Kristina | Other (J): 1,600,000 | EDGAR |
| 2023-07-28 | 4 | VBI Vaccines Inc/BC (VBIV) | Grant/award (A): 52,500 (derivative) @ $0 | EDGAR |
| 2023-07-18 | 4 | VBI Vaccines Inc/BC (VBIV) | Purchase (P): 609,090 @ $1.65 · Purchase (P): 609,090 (derivative) | EDGAR |
| 2023-06-15 | 4 | Homology Medicines, Inc. (FIXX) | Grant/award (A): 23,000 (derivative) @ $0 | EDGAR |
| 2023-02-21 | 4 | Codiak BioSciences, Inc. (CDAK) | Option exercise (M): 8,750 · Option exercise (M): 8,750 (derivative) @ $0 | EDGAR |
| 2023-01-30 | 4 | VBI Vaccines Inc/BC (VBIV) | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2022-10-26 | 4 | Prime Medicine, Inc. (PRME) jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., CRANDELL KEITH, Burow Kristina | Conversion (C): 5,728,297 · Conversion (C): 5,728,297 · Purchase (P): 400,000 @ $17 · Purchase (P): 400,000 @ $17 · Conversion (C): 16,666,667 (derivative) @ $0 · Conversion (C): 16,666,664 (derivative) @ $0 · +2 more | EDGAR |
| 2022-09-15 | 4 | Codiak BioSciences, Inc. (CDAK) | Purchase (P): 5,000,000 · Purchase (P): 5,000,000 (derivative) | EDGAR |
| 2022-06-21 | 4 | Codiak BioSciences, Inc. (CDAK) | Grant/award (A): 7,500 (derivative) @ $0 · Grant/award (A): 1,500 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | Homology Medicines, Inc. (FIXX) | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2022-02-18 | 4 | Codiak BioSciences, Inc. (CDAK) | Grant/award (A): 8,750 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | VBI Vaccines Inc/BC (VBIV) | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2021-08-09 | 4 | DA32 Life Science Tech Acquisition Corp. (DALS) jointly with ARCH Venture Fund XI, L.P., ARCH Venture Partners XI, L.P., ARCH Venture Partners XI, LLC, NELSEN ROBERT, Burow Kristina | Other (J): 701,250 (derivative) @ $0 | EDGAR |
| 2021-08-03 | 4 | DA32 Life Science Tech Acquisition Corp. (DALS) jointly with ARCH Venture Fund XI, L.P., ARCH Venture Partners XI, L.P., ARCH Venture Partners XI, LLC, NELSEN ROBERT, Burow Kristina | Purchase (P): 1,600,000 @ $10 · Other (J): 650,000 @ $10 | EDGAR |
| 2021-07-20 | 4 | Erasca, Inc. (ERAS) jointly with ARCH Venture Partners X, LLC, ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., NELSEN ROBERT, CRANDELL KEITH, Burow Kristina | Conversion (C): 5,527,777 · Conversion (C): 5,527,777 · Conversion (C): 2,100,000 (derivative) · Conversion (C): 2,100,000 (derivative) · Conversion (C): 3,400,000 (derivative) · Conversion (C): 1,133,333 (derivative) · +2 more | EDGAR |
| 2021-06-23 | 4 | Verve Therapeutics, Inc. (VERV) jointly with ARCH Venture Partners X, LLC, ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., CRANDELL KEITH, NELSEN ROBERT, Burow Kristina | Conversion (C): 1,254,404 · Conversion (C): 1,254,405 · Conversion (C): 7,107,024 (derivative) · Conversion (C): 7,107,023 (derivative) · Conversion (C): 4,508,144 (derivative) · Conversion (C): 4,508,146 (derivative) | EDGAR |
| 2021-06-22 | 4 | Homology Medicines, Inc. (FIXX) | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2021-06-22 | 4 | Codiak BioSciences, Inc. (CDAK) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2021-02-10 | 4 | Sana Biotechnology, Inc. (SANA) jointly with ARCH Venture Fund X, L.P., CRANDELL KEITH, BYBEE CLINTON, Burow Kristina | Conversion (C): 10,156,250 · Conversion (C): 10,156,250 · Conversion (C): 11,718,750 · Conversion (C): 11,718,750 · Conversion (C): 3,687,500 (derivative) @ $0 · Conversion (C): 3,687,500 (derivative) @ $0 · +8 more | EDGAR |
| 2021-01-29 | 4 | VBI Vaccines Inc/BC (VBIV) | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2020-10-20 | 4 | Codiak BioSciences, Inc. (CDAK) | Conversion (C): 1,784,572 · Conversion (C): 420,368 · Purchase (P): 235,000 @ $15 · Conversion (C): 13,950,000 (derivative) · Conversion (C): 3,000,000 (derivative) | EDGAR |
| 2020-10-15 | 4 | Codiak BioSciences, Inc. (CDAK) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2020-09-01 | 4 | Pulmatrix, Inc. (PULM) | Disposition to issuer (D): 1,771 (derivative) · Grant/award (A): 1,771 (derivative) · Disposition to issuer (D): 111 (derivative) · Grant/award (A): 111 (derivative) · Disposition to issuer (D): 880 (derivative) · Grant/award (A): 880 (derivative) · +10 more | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-26 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1229592 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs